



## SmartPA Criteria Proposal

<b>Drug/Drug Class:</b>	Triglyceride Lowering Agents PDL Edit
<b>First Implementation Date:</b>	December 6, 2006
<b>Proposed Date:</b>	September 17, 2020
<b>Prepared For:</b>	MO HealthNet
<b>Prepared By:</b>	MO HealthNet/Conduent
<b>Criteria Status:</b>	<input checked="" type="checkbox"/> Existing Criteria <input type="checkbox"/> Revision of Existing Criteria <input type="checkbox"/> New Criteria

### Executive Summary

**Purpose:** The MO HealthNet Pharmacy Program will implement a state-specific preferred drug list.

**Why Issue Selected:** The fibric acid derivatives (fibrates) are designed to lower triglycerides and to raise high-density lipoprotein (HDL). Fibrates have been shown to lower triglycerides by as much as 35-50% and to raise HDL by as much as 15-25%. Omega-3-Fatty Acids are present in fatty fish such as mackerel, lake trout, herring sardines, albacore tuna, and salmon and also in dietary supplements of fish oil concentrates, but large quantities of these products are required to reach therapeutic doses. Lovaza is a highly purified ethyl ester concentrate of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), two kinds of omega-3-fatty acids. The major effect of Lovaza is to lower TGs, although the mechanism of action is not entirely understood. These agents should be used in addition to a diet restricted in saturated fat and cholesterol when the individual response has been inadequate.

Total program savings for the PDL classes will be regularly reviewed.

Program-Specific Information:	Preferred Agents	Non-Preferred Agents
	<ul style="list-style-type: none"> <li>Fenofibrate 54, 67, 134, 160, 200mg (gen Lofibra®)</li> <li>Fenofibrate 48, 145mg (gen Tricor®)</li> <li>Gemfibrozil</li> </ul>	<ul style="list-style-type: none"> <li>Antara®</li> <li>Fenofibrate (gen Antara®)</li> <li>Fenofibrate (gen Fenoglide®)</li> <li>Fenofibrate (gen Lipofen®)</li> <li>Fenofibrate (gen Triglide®)</li> <li>Fenofibric Acid (gen Fibracor®)</li> <li>Fenofibric Acid (gen Trilipix®)</li> <li>Fenoglide®</li> <li>Lipofen®</li> <li>Lofibra®</li> <li>Lopid®</li> <li>Lovaza®</li> <li>Omega-3 Acid Ethyl Esters</li> <li>Tricor®</li> <li>Triglide®</li> <li>Triklo</li> <li>Trilipix®</li> <li>Vascepa®</li> </ul>

Type of Criteria: ☐ Increased risk of ADE  
☐ Appropriate Indications

☒ Preferred Drug List  
☐ Clinical Edit

Data Sources: ☒ Only Administrative Databases

☐ Databases + Prescriber-Supplied

## Setting & Population

- Drug class for review: Triglyceride Lowering Agents
- Age range: All appropriate MO HealthNet participants

## Approval Criteria

- Failure to achieve desired therapeutic outcomes with trial on 2 or more preferred agents
  - Documented trial period for preferred agents **OR**
  - Documented ADE/ADR to preferred agents **OR**
  - For Lovaza or Vascepa therapy: Triglyceride levels  $\geq$  500mg/dl allow first line therapy access

## Denial Criteria

- Lack of adequate trial on required preferred agents
- Therapy will be denied if all approval criteria are not met

## Required Documentation

Laboratory Results: ☒  
 MedWatch Form: ☐

Progress Notes: ☐  
 Other: ☐

### SmartPA PDL Proposal Form

© 2020 Conduent Business Services, LLC. All rights reserved. Conduent™ and Conduent Design™ are trademarks of Conduent Business Services, LLC in the United States and/or other countries.

Other company trademarks are also acknowledged.

## Disposition of Edit

Denial: Exception Code "0160" (Preferred Drug List)  
Rule Type: PDL

## Default Approval Period

1 year

## References

1. Evidence-Based Medicine and Fiscal Analysis: "Triglyceride Lowering Agents – Therapeutic Class Review", Conduent Business Services, L.L.C., Richmond, VA; July 2020.
2. Evidence-Based Medicine Analysis: "Triglyceride Lowering Agents", UMKC-DIC; June 2020.
3. Lippincott, Williams, Wilkins. PDR Electronic Library, Montvale NJ; 2020.
4. USPDI, Micromedex; 2020.
5. Facts and Comparisons eAnswers (online); 2020 Clinical Drug Information, LLC.